Expert Rev Clin Immunol. 2024 Jul 23. doi: 10.1080/1744666X.2024.2383236. Online ahead of print.
ABSTRACT
INTRODUCTION: Kawasaki disease (KD) is a medium vessel vasculitis mainly affecting children below the age of 5. KD is the leading cause of acquired heart disease in developed countries. Diagnosis of KD is clinical and there are no pathognomonic laboratory tests to confirm the diagnosis. There is paucity of studies that have utilized proteomic approach for biomarker discovery in KD. Identification of these biomarkers may be helpful for early and more effective diagnosis and may aid in the treatment of KD.
AREA COVERED: The present review focuses on studies that have utilized the proteomic approach in identification of biomarkers in patients with KD. We have divided these biomarkers into 3 different categories, the biomarkers used for (A) Assessment of risk of KD; (B) Assessment of risk of CAAs; and (C) for assessment of treatment resistance.
EXPERT OPINION: Efforts to improve the clinical and diagnostic evaluation of KD have focused on general markers of inflammation which are not specific for KD. Identification of a proteomic based biomarker can reliably and specifically differentiate KD from other disease and would help in the prompt diagnosis. Comprehensive analysis of serum proteome of patients with KD may be helpful in identifying candidate protein biomarkers.
PMID:39041312 | DOI:10.1080/1744666X.2024.2383236
